| Literature DB >> 33274201 |
María G Prado-Ochoa1, Maribel Strassburger-Madrigal2, Rafael Camacho-Carranza3, Jesús J Espinosa-Aguirre3, Ana M Velázquez-Sánchez4, Victor H Vázquez-Valadez4, Enrique Angeles4, Fernando Alba-Hurtado1, Marco A Muñoz-Guzmán1.
Abstract
Ethyl-4-bromophenyl-carbamate (LQM 919) and Ethyl-4-chlorophenyl-carbamate (LQM 996) are compounds that inhibit egg-laying and hatching of tick larvae that are resistant to conventional ixodicides. The structure-activity relationship (SAR) to get the endpoint predictions of mutagenicity and carcinogenicity of the LQM 919 and LQM 996 was performed and the absence of mutagenicity was confirmed by Ames test. SAR analysis show no structural alerts indicating the ability of ethyl-carbamates to bind biomolecules or estrogen receptors. Endpoint of mutagenicity with and without metabolic activation showed that the ethyl-carbamates were negative (p <0.05) for mutagenicity induction in strains TA97, TA98, TA102, TA1535, TA1537 and TA1538 of Salmonella typhimurium. Pre-incubation with different ethyl-carbamate concentrations did not increase the number of spontaneously reverting colonies; moreover, the compounds did not induce a concentration-dependent increase in the number of reverting colonies in any of the strains used. This confirmed the absence of mutagenic activity in this test system. Exogenous metabolic activation did not modify these observations; suggesting that no metabolites with mutagenic activity were present. The endpoint of carcinogenicity in rats were negative for LQM 919 (p <0.05,) and LQM 996 (p <0.001). The results of the present study strongly suggest that ethyl-carbamates do not represent a risk for cancer in mammals.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33274201 PMCID: PMC7700028 DOI: 10.1155/2020/2981681
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Nomenclature, chemical structure and characteristics of ethyl-carbamates.
| LQM 919 | LQM 996 | |
|---|---|---|
| Chemical structure |
|
|
| Molecular weight | 244 | 199.63 |
| SMILES | CCOC(=O)Nc1ccc(Br)cc1 | CCOC(=O)Nc1ccc(cl)cc1 |
| Descriptors | Log Kow 3.13 | Log Kow 2.89 |
Profiling results of Structure-Activity Relationship (SAR) analysis of ixodicidal ethyl-carbamates.
| Chemical or biological mechanism | LQM 919 | LQM 996 |
|---|---|---|
| DNA binding by OECD | No alert found | No alert found |
| Estrogen receptor binding | Non binder, without OH or NH2 group | Non binder, without OH or NH2 group |
| Protein binding by OECD | No alert found | No alert found |
| Superfragments | No superfragment | No superfragment |
| Toxic hazard classification by Cramer (original) | High (class III) | High (class III) |
| US-EPA new chemical categories | Neutral organics | Neutral organics |
Predictions of mutagenicity of ethyl-carbamates on different strains of Salmonella typhimurium with and without S9 metabolic activation.
| CARBAMATE | Strain | With S9 activation | P-value | Without S9 activation | P-value |
|---|---|---|---|---|---|
| LQM 919 | TA 97 | Negative | p <0.001∗∗∗ | Negative | p =0.100 |
| TA 98 | Negative | p <0.001∗∗∗ | Negative | p <0.05∗ | |
| TA 102 | Negative | p <0.01∗∗ | Negative | p <0.01∗∗ | |
| TA 1535 | Negative | p <0.001∗∗∗ | Negative | p <0.01∗∗ | |
| TA 1537 | Negative | p <0.001∗∗∗ | Negative | p <0.05∗ | |
| TA 1538 | Negative | p <0.001∗∗∗ | Negative | p <0.001∗∗∗ | |
| LQM 996 | TA 97 | Negative | p <0.001∗∗∗ | Negative | p <0.001∗∗∗ |
| TA 98 | Negative | p <0.001∗∗∗ | Negative | p <0.01∗∗ | |
| TA 102 | Negative | p <0.01∗∗ | Negative | p <0.001∗∗∗ | |
| TA 1535 | Negative | p <0.001∗∗∗ | Negative | p <0.01∗∗ | |
| TA 1537 | Negative | p <0.001∗∗∗ | Negative | p <0.01∗∗ | |
| TA 1538 | Negative | p <0.01∗∗ | Negative | p <0.001∗∗∗ |
∗ moderate confidence; ∗∗ strong confidence; ∗∗∗ very strong confidence.
Figure 1Read across prediction of summary carcinogenicity from LQM 919. The red dot represents the predicted value for target chemical (LQM 919), brown dots represent the observed value for the target neighbours (analogues) used for read-across and blue dots represent the experimental results available for the analogues but not used for read-across. Predicted LQM 919 value: “Negative”, p <0.001.
Mutagenicity of carbamate LQM 919 towards Salmonella typhimurium TA98, TA100, TA1535, TA1537 and TA102 strain with or without S9 metabolic activation.
| No. of | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Concentration (mg/mL) | TA98 | TA100 | TA1535 | TA1537 | TA102 | |||||
| -S9 | +S9 | -S9 | +S9 | -S9 | +S9 | -S9 | +S9 | -S9 | +S9 | |
| 0 (-) | 18.5 ± 3.2 | 27.7 ± 2.5 | 104.1 ± 10.8 | 120 ± 9 | 9.1 ± 3.9 | 16.5 ± 1.9 | 9.1 ± 3 | 14.6 ± 3 | 319.5 ± 75.7 | 330 ± 66 |
| 0.1 | 16.3 ± 4.9 | 31 ± 6.2 | 112 ± 20.7 | 133.3 ± 10.5 | 10 ± 1.7 | 13.6 ± 1.5 | 10.6 ± 2.5 | 14 ± 5.2 | 225 ± 26.5 | 347.6 ± 41.5 |
| 0.2 | 20.3 ± 4.1 | 28.7 ± 7.1 | 107.6 ± 15.8 | 118.6 ± 4.5 | 6 ± 3.4 | 9.3 ± 2.0 | 4.3 ± 0.5 | 9.6 ± 2 | 219.6 ± 5.8 | 265 ± 13 |
| 0.4 | 16.3 ± 2 | 30 ± 7.5 | 125.6 ± 19.4 | 89.6 ± 19.8 | 11 ± 2.6 | 11 ± 4.3 | 6.33 ± 3.2 | 9.3 ± 2 | 118.3 ± 21.9 | 250.3 ± 15.8 |
| 0.5 | 20.3 ± 4.5 | 32.3 ± 8.6 | 78 ± 2 | 106.3 ± 16.8 | 4 ± 3.4 | 12 ± 3 | 4 ± 2.6 | 9.6 ± 1.5 | 80.6 ± 2.8 | 101.6 ± 89.2 |
| 1 | 10 ± 5.2 | 25.6 ± 5.1 | 35 ± 22.9 | 28.3 ± 19.4 | 5 ± 1 | 6.6 ± 1.5 | 2 ± 2 | 6 ± 4.5 | 3.3 ± 5.7 | 0 |
| Limit value: | 37 | 55.4 | 208.2 | 240 | 18.2 | 33 | 18.2 | 29.2 | 639 | 660 |
| Positive controls: | ||||||||||
| 2-NF | 2017 ± 460 | |||||||||
| Sodium azide | 1666 ± 99 | 731 ± 77.2 | ||||||||
| Picrolonic acid | 48.33 ± 25.1 | |||||||||
| 4-NQO | 1573 ± 61 | |||||||||
| 2-AA | 1831 ± 163 | 2277 ± 146 | 765 ± 45 | 441 ± 99 | 2050 ± 93 | |||||
S9 = Microsomal fraction of liver of rats treated with phenobarbital and beta-naphthoflavone enriched with NADP and glucose-6-P; 2-NF =2-nitrofluorene; 4-NQO =4-nitroquinolido N-oxide; 2-AA =2-aminoanthracene.
Mutagenicity of carbamate LQM 996 towards Salmonella typhimurium TA98, TA100, TA1535, TA1537 and TA102 strain with or without S9 metabolic activation.
| No. of | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Concentration (mg/mL) | TA98 | TA100 | TA1535 | TA1537 | TA102 | |||||
| -S9 | +S9 | -S9 | +S9 | -S9 | +S9 | -S9 | +S9 | -S9 | +S9 | |
| 0 (-) | 18.5 ± 3.2 | 27.7 ± 2.5 | 104.1 ± 10.8 | 120 ± 9 | 9.1 ± 3.9 | 16.5 ± 1.9 | 9.1 ± 3 | 14.6 ± 3 | 319.5 ± 75.7 | 330 ± 66 |
| 0.1 | 20.3 ± 4.1 | 28.3 ± 6.1 | 94.6 ± 27.7 | 92.6 ± 5.5 | 8.3 ± 3.2 | 7.6 ± 4.6 | 7.3 ± 3.2 | 8.3 ± 1.1 | 395.3 ± 6.1 | 473 ± 17.5 |
| 0.2 | 20 ± 5 | 30.3 ± 4.0 | 96 ± 3 | 101.3 ± 12.3 | 4 ± 1.7 | 10.6 ± 3.5 | 4.6 ± 2 | 8.3 ± 2.5 | 251.6 ± 49.8 | 419.6 ± 31.6 |
| 0.4 | 17 ± 4 | 22.6 ± 8 | 83.6 ± 17.6 | 95 ± 4.3 | 2.6 ± 1.5 | 11.6 ± 1.5 | 1.6 ± 2.8 | 5.3 ± 3 | 241.3 ± 49.1 | 367.3 ± 58.2 |
| 0.5 | 18.3 ± 4 | 30.3 ± 1.1 | 96.6 ± 12.5 | 81.6 ± 16.6 | 2.6 ± 2.3 | 4.6 ± 3.2 | 0 | 0 | 194.3 ± 43 | 335.6 ± 18 |
| 1 | 13 ± 1.7 | 21.3 ± 3 | 34.6 ± 26.2 | 0 | 0 | 6.6 ± 2.8 | 0 | 0 | 150 ± 16.7 | 185.3 ± 29.2 |
| Limit value: | 37 | 55.4 | 208.2 | 240 | 18.2 | 33 | 18.2 | 29.2 | 639 | 660 |
| Positive controls: | ||||||||||
| 2-NF | 2017 ± 460 | |||||||||
| Sodium azide | 1666 ± 99 | 731 ± 77.2 | ||||||||
| Picrolonic acid | 48.33 ± 25.1 | |||||||||
| 4-NQO | 1573 ± 61 | |||||||||
| 2-AA | 1831 ± 163 | 2277 ± 146 | 765 ± 45 | 441 ± 99 | 2050 ± 93 | |||||
S9 = Microsomal fraction of liver of rats treated with phenobarbital and beta-naphthoflavone enriched with NADP and glucose-6-P; 2-NF =2-nitrofluorene; 4-NQO =4-nitroquinolido N-oxide; 2-AA =2-aminoanthracene.